J

Jafron Biomedical Co Ltd
SZSE:300529

Watchlist Manager
Jafron Biomedical Co Ltd
SZSE:300529
Watchlist
Price: 29.87 CNY -4.57% Market Closed
Market Cap: 24.1B CNY
Have any thoughts about
Jafron Biomedical Co Ltd?
Write Note

Jafron Biomedical Co Ltd
Net Change in Cash

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Jafron Biomedical Co Ltd
Net Change in Cash Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Change in Cash CAGR 3Y CAGR 5Y CAGR 10Y
J
Jafron Biomedical Co Ltd
SZSE:300529
Net Change in Cash
-ÂĄ935.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
A
APT Medical Inc
SSE:688617
Net Change in Cash
ÂĄ1B
CAGR 3-Years
180%
CAGR 5-Years
146%
CAGR 10-Years
N/A
J
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SZSE:002223
Net Change in Cash
ÂĄ81.5m
CAGR 3-Years
-44%
CAGR 5-Years
N/A
CAGR 10-Years
7%
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
Net Change in Cash
ÂĄ2.8B
CAGR 3-Years
N/A
CAGR 5-Years
-19%
CAGR 10-Years
N/A
L
Lepu Medical Technology Beijing Co Ltd
SZSE:300003
Net Change in Cash
-ÂĄ1.4B
CAGR 3-Years
N/A
CAGR 5-Years
-23%
CAGR 10-Years
-31%
Shanghai United Imaging Healthcare Co Ltd
SSE:688271
Net Change in Cash
-ÂĄ2.1B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Jafron Biomedical Co Ltd
Glance View

Market Cap
24.1B CNY
Industry
Health Care

Jafron Biomedical Co., Ltd. engages in the research, development, production, and sale of hemoperfusion products. The company is headquartered in Zhuhai, Guangdong and currently employs 2,887 full-time employees. The company went IPO on 2016-08-02. is a China-based company principally engaged in the research, design, manufacture and distribute of biological materials and medical equipment. The Company’s products include disposable hemoperfusion devices, hemoperfusion machine, disposable bilirubin adsorbers, DX-10 blood purification machine, suture needle, as well as resins bandage, among others. The Company’s products are applied in uremia, poisoning, severe liver diseases, autoimmune diseases, as well as multisystem organ failure, among others. The Company’s products are applied in 31 provinces, more than 3000 hospitals in China.

Intrinsic Value
46.98 CNY
Undervaluation 36%
Intrinsic Value
Price
J

See Also

What is Jafron Biomedical Co Ltd's Net Change in Cash?
Net Change in Cash
-935.8m CNY

Based on the financial report for Jun 30, 2024, Jafron Biomedical Co Ltd's Net Change in Cash amounts to -935.8m CNY.

Back to Top